Metformin combined with progesterone improves efficacy and reduces adverse reactions in early endometrial cancer

Key Points

• Efficacy increases with the combination of metformin and progesterone in treating early endometrial cancer, leading to better patient outcomes.
• Combined treatment resulted in a significant reduction of serum tumor marker levels, enhancing treatment monitoring.
• The analysis shows substantial decreases in BMI and adverse reactions compared to traditional approaches in early endometrial cancer therapy.
• These findings may contribute to improved management strategies in early endometrial cancer, warranting further clinical investigation.